Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
HOW TO PREDICT RESPONSE TO RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS
15 septembra, 2020 7:11 pmAuthor(s): María Isabel Montero, Marta Reinoso, Laura Pérez-Ortega, et. al. EHA Library. Reinoso M. May 16, 2019; 268124; PB2215 ...
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL
15 septembra, 2020 7:11 pmAuthor(s): Francisco Cervantes, Heinz Gisslinger, Atanas Radinoff, et. al. EHA Library. Cervantes F. Jun 15, 2019; 267082; PS1465 Abstract:...
Novinky z kongresu: Myeloproliferatívna neoplázia
15 septembra, 2020 7:11 pmPo šiestich rokoch sa kongres európskej hematologickej asociácie vrátil do hlavného mesta Holandska. Program kongresu zahŕňal všetky podkategórie hematológie a choroby...
RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE III STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA
15 septembra, 2020 7:10 pmAuthor(s): Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, et. al. EHA Library. Mateos M. Jun 15, 2019; 267406; S823 Abstract:...
SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS
15 septembra, 2020 7:10 pmAuthor(s): Cristina Gasparetto, Suzanne Lentzsch, Gary Schiller, et. al. EHA Library. J. Gasparetto C. Jun 16, 2019; 267360; S1606 ...
A PHASE III STUDY OF VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
15 septembra, 2020 7:10 pmAuthor(s): Shaji Kumar, Simon Harrison, Michele Cavo, et. al. EHA Library. Kumar S. Jun 16, 2019; 273254; LB2601 Abstract:...
Pomalidomide + Bortezomib + Low-Dose Dexamethasone vs Bortezomib + Low-Dose Dexamethasone After One Prior Line of Therapy in Patients With Lenalidomide-Pretreated Multiple Myeloma: Subgroup Analysis of the Phase III OPTIMISMM Trial
15 septembra, 2020 7:10 pmAuthor(s): Meletios Dimopoulos, Katja Weisel, Philippe Moreau, et. al. EHA Library. Dimopoulos M. Jun 14, 2019; 266394; PF595 Abstract:...
NOVINKY Z KONGRESU – MNOHOPOČETNÝ MYELÓM
15 septembra, 2020 7:10 pmPokroky v liečbe mnohopočetného myelómu sú z roka na rok viditeľnejšie a práve stretnutia typu EHA sú miestom, kde dochádza k ich najväčšej prezentácii....
SAFETY AND EFFICACY OF ROMIPLOSTIM IN OVER 200 CHILDREN WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN AN INTEGRATED DATABASE OF 5 CLINICAL TRIALS
15 septembra, 2020 7:10 pmAuthor(s): Michael Tarantino, Jenny Despotovic, John Grainger, et. al. EHA Library. Cooper N. Jun 14, 2019; 266488 Abstract: PF689...
ADJUSTED INDIRECT COMPARISON OF ELTROMBOPAG RELATIVE TO RITUXIMAB OR SPLENECTOMY IN SECOND LINE TREATMENT FOR CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA
15 septembra, 2020 7:10 pmAuthor(s): Jorge Felix, Valeska Andreozzi, Bjorn Vandewalle, et. al. EHA Library. Félix J. May 16, 2019; 267630 Abstract: PB2247...